AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGENUS INC Director's Dealing 2023

Aug 28, 2023

34023_dirs_2023-08-28_0078d8e0-5ead-414c-9666-6ca7f47099ed.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2023-08-24

Reporting Person: AGENUS INC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-24	Common Stock	P	170244	$1.5443	Acquired	21692401	Direct
2023-08-28	Common Stock	P	12808	$1.4499	Acquired	21705209	Direct

Footnotes

F1: Open market purchases reported on this line occurred at a weighted average price of $1.5443 (range of $1.52 to $1.55).

F2: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3: Open market purchases reported on this line occurred at a weighted average price of $1.4499 (range of $1.44 to $1.45).